2023
Risk of Subsequent Neoplasms in Childhood Cancer Survivors After Radiation Therapy: A PENTEC Comprehensive Review
Casey D, Vogelius I, Brodin N, Roberts K, Avanzo M, Moni J, Owens C, Ronckers C, Constine L, Bentzen S, Olch A. Risk of Subsequent Neoplasms in Childhood Cancer Survivors After Radiation Therapy: A PENTEC Comprehensive Review. International Journal Of Radiation Oncology • Biology • Physics 2023, 119: 640-654. PMID: 37777927, DOI: 10.1016/j.ijrobp.2023.07.025.Peer-Reviewed Original ResearchChildhood cancer survivorsCancer survivorsRadiation therapySubsequent meningiomaLung cancerCNS neoplasmsSubsequent neoplasmsSubsequent sarcomaRT dosePrimary diagnosisHigh riskPediatric Normal Tissue EffectsRadiation dose-response relationshipSubsequent lung cancerPrior radiation therapyTreatment-related factorsExcess absolute riskPrimary cancer diagnosisERR/GyNormal tissue effectsSpecific chemotherapeutic agentsDose-response relationshipHigh-dose volumeSignificant contributory roleERR/
2022
Risk of Subsequent Central Nervous System Neoplasms in Childhood Cancer Survivors after Radiation Therapy: Results from the Pediatric Normal Tissue Effects in the Clinic (PENTEC) Collaboration
Casey D, Brodin P, Roberts K, Vogelius I, Avanzo M, Moni J, Owens C, Ronckers C, Constine L, Bentzen S, Olch A. Risk of Subsequent Central Nervous System Neoplasms in Childhood Cancer Survivors after Radiation Therapy: Results from the Pediatric Normal Tissue Effects in the Clinic (PENTEC) Collaboration. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: s122-s123. DOI: 10.1016/j.ijrobp.2022.07.568.Peer-Reviewed Original ResearchSubsequent malignant tumorChildhood cancer survivorsMalignant CNS tumorsSubsequent meningiomaExcess odds ratioMalignant tumorsRadiation therapyCancer survivorsRT doseCNS tumorsOdds ratioHigh riskPediatric Normal Tissue EffectsPrior cranial radiation therapyCentral nervous system neoplasmsRadiation dose-response relationshipMalignant CNS tumorPrimary cancer diagnosisCranial radiation therapyNervous system neoplasmsIndependent patient cohortsDifferent dose intervalsNormal tissue effectsDose-response relationshipMATERIAL/METHODS
2005
PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy
Roberts KB, Manus MP, Hicks RJ, Rischin D, Wirth A, Wright GM, Ball DL. PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy. Lung Cancer 2005, 47: 49-57. PMID: 15603854, DOI: 10.1016/j.lungcan.2004.06.014.Peer-Reviewed Original ResearchConceptsRadical radiotherapyExtensive diseaseNon-small cell lung cancerFluorodeoxyglucose positron emission tomographyRadical RTGood performance statusEvidence of diseaseAppropriateness of managementCell lung cancerEarly tumor progressionConcurrent chemotherapyIntrathoracic recurrenceThoracic recurrenceImpact of PETLimited diseaseProspective databaseTreatment intentPerformance statusRT doseSupportive careFurther patientsInflammatory changesUnexplained painClinical outcomesResidual tumor
2000
Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy
Elconin J, Roberts K, Rizzieri D, Vermont C, Clough R, Kim C, Dodge R, Prosnitz L. Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 1097-1105. PMID: 11072168, DOI: 10.1016/s0360-3016(00)00695-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedNeoplasm StagingPrednisoneProcarbazineRadiotherapy DosageRetrospective StudiesTreatment FailureVinblastineVincristineConceptsLarge mediastinal adenopathyHodgkin's disease patientsComplete responseDisease patientsInduction chemotherapyInduction failureGallium scanMediastinal adenopathyModality therapyRT doseComplete clinical stagingLow-dose radiotherapyResidual radiographic abnormalitiesCycles of chemotherapyFailure-free survivalPhase III trialsPatterns of failureConsolidation radiationChemotherapy regimensCR patientsIII trialsOverall survivalClinical stagingHD patientsRadiographic abnormalities